Trial intelligence / Profile preview

RP901 in Knee Osteoarthritis (Phase II)

CTR20240894Phase 2Active

Sponsor
Runjia Pharmaceutical
Start
Mar 2024
Modality
Small Molecules
Countries
1
01

Overview

A Phase 2 trial of RP901 in knee osteoarthritis (OA), sponsored by Runjia Pharmaceutical. Started Mar 2024; status: active.

02

Drugs

RP901
03

Conditions

knee osteoarthritis (OA)

Beyond the preview

Go deeper on CTR20240894.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20240894.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call